CA2086434C
(en)
*
|
1990-07-23 |
1998-09-22 |
John A. Lowe, Iii |
Quinuclidine derivatives
|
US5750542A
(en)
*
|
1993-09-28 |
1998-05-12 |
Pfizer |
Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
|
US5716965A
(en)
*
|
1991-05-22 |
1998-02-10 |
Pfizer Inc. |
Substituted 3-aminoquinuclidines
|
US5292726A
(en)
*
|
1991-05-22 |
1994-03-08 |
Merck & Co., Inc. |
N,N-diacylpiperazines
|
AU657552B2
(en)
*
|
1991-05-31 |
1995-03-16 |
Pfizer Inc. |
Quinuclidine as substance P antagonists
|
JPH07110850B2
(ja)
*
|
1991-06-20 |
1995-11-29 |
フアイザー・インコーポレイテツド |
窒素含有複素環化合物のフルオロアルコキシベンジルアミノ誘導体
|
TW202432B
(de)
*
|
1991-06-21 |
1993-03-21 |
Pfizer |
|
MY110227A
(en)
*
|
1991-08-12 |
1998-03-31 |
Ciba Geigy Ag |
1-acylpiperindine compounds.
|
JP2614408B2
(ja)
*
|
1991-11-12 |
1997-05-28 |
ファイザー・インコーポレーテッド |
サブスタンスp受容体アンタゴニストとしての非環式エチレンジアミン誘導体
|
FR2688219B1
(fr)
|
1992-03-03 |
1994-07-08 |
Sanofi Elf |
Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
|
DE69331190T2
(de)
*
|
1992-05-18 |
2002-04-18 |
Pfizer |
Überbrückte azabicyclische derivate als substanz p antagonisten
|
US6048859A
(en)
|
1992-06-29 |
2000-04-11 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
US5637699A
(en)
*
|
1992-06-29 |
1997-06-10 |
Merck & Co., Inc. |
Process for preparing morpholine tachykinin receptor antagonists
|
US5719147A
(en)
*
|
1992-06-29 |
1998-02-17 |
Merck & Co., Inc. |
Morpholine and thiomorpholine tachykinin receptor antagonists
|
GB2268931A
(en)
*
|
1992-07-22 |
1994-01-26 |
Merck Sharp & Dohme |
Azabicyclic tachykinin-receptor antagonists
|
GB9216911D0
(en)
*
|
1992-08-10 |
1992-09-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
JP2909214B2
(ja)
*
|
1992-08-19 |
1999-06-23 |
フアイザー・インコーポレイテツド |
置換ベンジルアミノ窒素含有非芳香族複素環化合物
|
US5387595A
(en)
*
|
1992-08-26 |
1995-02-07 |
Merck & Co., Inc. |
Alicyclic compounds as tachykinin receptor antagonists
|
US5837711A
(en)
*
|
1992-10-28 |
1998-11-17 |
Pfizer Inc. |
Substituted quinuclidines as substance P antagonists
|
EP0668863B1
(de)
*
|
1992-11-12 |
1997-01-08 |
Pfizer Inc. |
Chinuclidin derivat als substanz p antagonist
|
US5344830A
(en)
*
|
1992-12-10 |
1994-09-06 |
Merck & Co., Inc. |
N,N-diacylpiperazine tachykinin antagonists
|
US5830854A
(en)
*
|
1992-12-14 |
1998-11-03 |
Merck Sharp & Dohme, Limited |
Method of treating cystic fibrosis using a tachykinin receptor antagonist
|
US5340826A
(en)
*
|
1993-02-04 |
1994-08-23 |
Pfizer Inc. |
Pharmaceutical agents for treatment of urinary incontinence
|
US5393762A
(en)
*
|
1993-06-04 |
1995-02-28 |
Pfizer Inc. |
Pharmaceutical agents for treatment of emesis
|
EP0655246A1
(de)
*
|
1993-11-30 |
1995-05-31 |
Pfizer Inc. |
Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
|
IT1271462B
(it)
*
|
1993-12-03 |
1997-05-28 |
Menarini Farma Ind |
Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
|
TW385308B
(en)
*
|
1994-03-04 |
2000-03-21 |
Merck & Co Inc |
Prodrugs of morpholine tachykinin receptor antagonists
|
US6203803B1
(en)
|
1994-12-14 |
2001-03-20 |
Societe L'oreal S.A. |
Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
|
FR2719474B1
(fr)
*
|
1994-05-05 |
1996-05-31 |
Oreal |
Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
|
FR2719476B1
(fr)
*
|
1994-05-05 |
1997-05-23 |
Oreal |
Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
|
TW397825B
(en)
*
|
1994-10-14 |
2000-07-11 |
Novartis Ag |
Aroyl-piperidine derivatives
|
FR2725900B1
(fr)
*
|
1994-10-21 |
1997-07-18 |
Sanofi Sa |
Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
|
IL116249A
(en)
*
|
1994-12-12 |
2003-07-06 |
Pfizer |
Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
|
FR2728166A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Composition topique contenant un antagoniste de substance p
|
FR2728165A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
|
FR2728169A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
|
FR2729954B1
(fr)
|
1995-01-30 |
1997-08-01 |
Sanofi Sa |
Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
|
FR2741262B1
(fr)
|
1995-11-20 |
1999-03-05 |
Oreal |
Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
|
WO1998046601A1
(en)
*
|
1997-04-11 |
1998-10-22 |
Eli Lilly And Company |
Composition for treating pain
|
DE69907220T2
(de)
*
|
1998-08-25 |
2004-02-05 |
Novartis Ag |
Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie
|
US7101547B1
(en)
|
1999-01-22 |
2006-09-05 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
|
JP2001172178A
(ja)
*
|
1999-10-25 |
2001-06-26 |
Pfizer Prod Inc |
偏頭痛治療用のnk−1レセプターアンタゴニスト及びエレトリプタン
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
EP1246806B1
(de)
|
1999-11-03 |
2008-02-27 |
AMR Technology, Inc. |
Arly- und heteroaryl-substituierte tetrahydroisoquinoline und ihre verwendung als hemmer der wiederaufnahme von norepinephrin, dopamin und serotonin
|
KR20020069362A
(ko)
*
|
2000-01-20 |
2002-08-30 |
에자이 가부시키가이샤 |
함질소환 화합물 및 이들을 포함하는 의약 조성물
|
AU7334901A
(en)
|
2000-07-11 |
2002-01-21 |
Du Pont Pharm Co |
Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
|
US20020049211A1
(en)
*
|
2000-09-06 |
2002-04-25 |
Sobolov-Jaynes Susan Beth |
Combination treatment for depression and anxiety
|
DK1319000T3
(da)
|
2000-09-20 |
2009-02-16 |
Aprea Ab |
Anvendelse af 1-azabicyclo(2,2,2)oktan-3-on-derivater til behandling af cancertumorer
|
EP1192952A3
(de)
*
|
2000-09-28 |
2003-03-26 |
Pfizer Products Inc. |
Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
|
SE0400708D0
(sv)
*
|
2004-03-22 |
2004-03-22 |
Aprea Ab |
New compounds and use thereof
|
WO2006020049A2
(en)
|
2004-07-15 |
2006-02-23 |
Amr Technology, Inc. |
Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
ES2382814T3
(es)
|
2005-05-17 |
2012-06-13 |
Merck Sharp & Dohme Ltd. |
Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
|
US7956050B2
(en)
|
2005-07-15 |
2011-06-07 |
Albany Molecular Research, Inc. |
Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2770486C
(en)
|
2006-09-22 |
2014-07-15 |
Merck Sharp & Dohme Corp. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
PL2109608T3
(pl)
|
2007-01-10 |
2011-08-31 |
Msd Italia Srl |
Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
|
EP2117538A1
(de)
|
2007-01-24 |
2009-11-18 |
Glaxo Group Limited |
Pharmazeutische zusammensetzungen mit 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
JP5501227B2
(ja)
|
2007-06-27 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
|
JP2011515343A
(ja)
|
2008-03-03 |
2011-05-19 |
タイガー ファーマテック |
チロシンキナーゼ阻害薬
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
AR071997A1
(es)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
DK2429296T3
(en)
|
2009-05-12 |
2018-03-12 |
Albany Molecular Res Inc |
7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
|
JP5739415B2
(ja)
|
2009-05-12 |
2015-06-24 |
ブリストル−マイヤーズ スクウィブ カンパニー |
(S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
|
KR20120034644A
(ko)
|
2009-05-12 |
2012-04-12 |
알바니 몰레큘라 리써치, 인크. |
아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
|
US8859776B2
(en)
|
2009-10-14 |
2014-10-14 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
EP2584903B1
(de)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Neue heterozyklische verbindungen als erk-hemmer
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
|
RU2624045C2
(ru)
|
2010-08-17 |
2017-06-30 |
Сирна Терапьютикс,Инк |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP2632472B1
(de)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Durch rna-interferenz vermittelte inhibition einer genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
CA2882950A1
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
US20140206667A1
(en)
|
2012-11-14 |
2014-07-24 |
Michela Gallagher |
Methods and compositions for treating schizophrenia
|
RU2660349C2
(ru)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Композиции и способы для лечения злокачественной опухоли
|
WO2014100065A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
EP3041938A1
(de)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Kreisförmige polynukleotide
|
EP3706742B1
(de)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
US20210309688A1
(en)
|
2018-08-07 |
2021-10-07 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|